Sucrose octasulfate

CAT:
804-HY-137273A
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Sucrose octasulfate - image 1

Sucrose octasulfate

  • Description:

    Sucrose octasulfate, a derivative of sulfated oligosaccharides, is a matrix metalloproteinase (MMP) inhibitor. Sucrose octasulfate stimulates the release of somatostatin-like immunoreactivity (SLI) from the stomach by acting directly on D cells in the gastric mucosa. Sucrose octasulfate exerts its ulcer-healing effect by releasing endogenous gastric somatostatin. Sucrose octasulfate can be used as a pharmaceutical excipient and significantly improves wound closure in diabetic foot ulcers caused by nerve ischemia and venous leg ulcers. Sucrose octasulfate can be used in the study of chronic wound healing[1][2][3].
  • UNSPSC:

    12352005
  • Target:

    MMP; Somatostatin Receptor
  • Related Pathways:

    GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology
  • Smiles:

    O=S(OC[C@@]1([C@H]([C@@H]([C@H](O1)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)OS(=O)(O)=O)(O)=O
  • Molecular Formula:

    C12H22O35S8
  • Molecular Weight:

    982.80
  • References & Citations:

    [1]Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer) : an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6 (3) :186-196.|[2]Dissemond J, et al. Sucrose Octasulfat – Evidenz in der Behandlung chronischer Wunden [Sucrose octasulfate-evidence in the treatment of chronic wounds]. Hautarzt. 2020 Oct;71 (10) :791-801. German. |[3]Lucey MR, et al. Sucrose octasulfate stimulates gastric somatostatin release. Am J Med. 1991 Aug 8;91 (2A) :52S-57S.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Reference compound1
  • Clinical Information:

    No Development Reported
  • CAS Number:

    [57680-56-5]